Global Biochip Market is segmented, by end users/applications, Hospitals, Biotechnology & Pharmaceutical Companies, Academic & Research Institutes, others. In molecular biology, biochips are fundamentally reduced laboratories that can achieve hundreds or thousands of instantaneous biochemical reactions. Biochips enable researchers to rapidly screen large numbers of biological analytes for a diversity of determinations, from disease diagnosis to detection of bioterrorism agents.
Digital microfluidic biochips have become one of the most promising technologies in many biomedical fields. In a digital microfluidic biochip, a group of (adjacent) cells in the microfluidic array can be arranged to work as storage, functional processes, as well as for conveying fluid droplets dynamically. Attendance of robust request for proteomics and genomics research concerned with products along with a wide-ranging drug development pipeline is predictable to drive the growth in the revenue. A mounting need to lessen turnaround time and reduce biological and clinical tests used for research & diagnosis has augmented demand for biochip and bio-array techniques.
Augmented technical developments connected to these procedures and a wide product portfolio on offer, due to new product launches, are expected to deliver researches with a variety of choice to precisely provide researchers with a range of choice to precisely suit their requirements. A biochip is the device that can comprise anywhere from tens to tens of millions of distinct sensor elements. The packaging of these sensor fundamentals on a solid substrate over a microscopic slid help in accomplishment lengthy tasks in an shortened time with high quantity and pace.
Different microchips, biochips are generally not electronic. Each biochip can be through of as a micro-reactor that can sense a precise analyte. The analyte can be a DNA, Protein, enzyme, antibody or any biological reactions, such as decoding genes, in a few seconds. Global Biochip Industry is segmented, by product into DNA Chips, lab-on-a-chip (LOAC) Protein Chips, others. DNA chips are accounted for the main share of revenue as a result of the high expenditure on research powerful to genomics and next-generation sequencing along with increasing demand for noticing and diagnosis of the genetic disorder.
The protein and DNA and LOACs have extensive applications for gene appearance,single nucleotide polymorphism genotyping, expression profiling, in-vitro diagnosis, high amount screening, point-of-care, drug discovery,tissue arrays,and agricultural biotechnology.Undoubtedly commercialized of products in company pipeline are predictable to be instrumental in enhancing the biochip industry potential.
Cumulative application of biochips in the medical sector for cancer conduct, drug research, and diagnostics is one of the major factors pouring the growth of the global biochips market. In addition, factors such as obtainability of molecular information, automation of biochemical processes finished the use of biochips and application of biochips for gene and protein identification are set to drive the global biochips market.
Global Biochip Market is segmented, By Geographical Region into North America, Europe, Japan, China, and Southeast Asia, India. In 2015, North America was conquered in the regional biochip manufacturing with a share of more than high of total revenue generated. The cumulative adaptation of the modified medicine, cumulative applications of biochips, principally for new drug discovery and developments in the biochip technologies are factors accountable for the regions leading share.
Asia Pacific is probable to observer the wildest growth due to the attendance of augmented healthcare spending on the R&D pertaining to genomics, proteomics, next generation sequencing as well as mounting patient’s awareness concerning developments in the diagnostics technologies and precisely in the emerging economies of the global biochip industry. Global Biochip Market Key Players include Abbott Laboratories, Agilent Technologies, PerkinElmer, Fluidigm Corporation, Illumina, GE Healthcare, Bio-Rad Laboratories, Cepheid, Thermo Fisher Scientific, and Roche Diagnostics.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Biochips in these regions, from 2012 to 2022 (forecast), covering
• North America
• Southeast Asia
Global Biochips market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• Affymetric Inc
• Illumina Inc
• GE Healthcare Ltd
• Agilent Technologies Inc
• Roche NimbleGen
• Life Technologies Corporation
• EMD Millipore
• Bio-Rad Laboratories Inc
• Abbott Laboratories
• Fluidigm Corporation
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• DNA chips
• Protein chips
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Biochips for each application, including
• Genomics and proteomics
• Drug screening and development
• Molecular diagnostics
• Microfluidic technologie
• Microarray and biosensors
Research Support Specialist, USA